Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors

Ancona, Pietro; Trentini, Alessandro; Terrazzan, Anna; Grassilli, Silvia; Navals, Pauline; Gates, Eric W.J.; Rosta, Valentina; Cervellati, Carlo; Bergamini, Carlo M.; Pignatelli, Angela; Keillor, Jeffrey W.; Taccioli, Cristian; Bianchi, Nicoletta

doi:10.1016/j.jmb.2024.168569

Journal of Molecular Biology

2024

DOI: 10.1016/j.jmb.2024.168569

|View full text |Cite

Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors

Pietro Ancona,

Alessandro Trentini,

Anna Terrazzan

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Transglutaminase 2 in breast cancer metastasis and drug resistance

Li,

Wang,

Hong

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Transglutaminase 2 (TG2) is a widely distributed multifunctional protein with various enzymatic and non-enzymatic activities. It is becoming increasingly evident that high levels of TG2 in tumors induce the occurrence of epithelial to mesenchymal transition (EMT) and the acquisition of stem cell-like phenotypes, promoting tumor metastasis and drug resistance. By regulating intracellular and extracellular signaling pathways, TG2 promotes breast cancer metastasis to lung, brain, liver and bone, as well as resistance to various chemotherapy drugs including docetaxel, doxorubicin, platinum and neratinib. More importantly, recent studies described the involvement of TG2 in PD-1/PD-L1 inhibitors resistance. An in-depth understanding of the role that TG2 plays in the progression of metastasis and drug resistance will offer new therapeutic targets for breast cancer treatment. This review covers the extensive and rapidly growing field of the role of TG2 in breast cancer. Based on the role of TG2 in EMT, we summarize TG2-related signaling pathways in breast cancer metastasis and drug resistance and discuss TG2 as a therapeutic target.

show abstract

Transglutaminase 2 in breast cancer metastasis and drug resistance

Li,

Wang,

Hong

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors

Cited by 1 publication

References 87 publications

Transglutaminase 2 in breast cancer metastasis and drug resistance

Transglutaminase 2 in breast cancer metastasis and drug resistance

Contact Info

Product

Resources

About